All In Biotech

Drug Trial Radar · NCT07140900

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 7, 2025

Primary completion

Oct 27, 2027

Study completion Oct 29, 2029

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

Conditions

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Interventions

  • XaluritamigDrug

    Participants will receive xaluritamig intravenously.

  • DarolutamideDrug

    Participants will receive darolutamide orally.

  • AbirateroneDrug

    Participants will receive abiraterone orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse EventsTime frame: Up to approximately 2.5 years
  2. Number of Participants with Treatment-related Adverse EventsTime frame: Up to approximately 2.5 years
  3. Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to approximately 2.5 years
  4. Number of Participants with Clinically Significant Changes in Clinical Laboratory TestsTime frame: Up to approximately 2.5 years

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • South Texas Accelerated Research Therapeutics - Carolinas

    Myrtle Beach, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, New South Wales, Australia

  • Cabrini Hospital

    Clayton, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Kantonsspital Graubuenden

    Chur, Switzerland

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland

  • Kantonsspital Sankt Gallen

    Sankt Gallen, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.